Document is current
Any future updates will be listed below
-
Authors
Alle, Gelsomina https://orcid.org/0000-0001-8091-2867
Scolnik, Marina https://orcid.org/0000-0002-0542-8001
Scaglioni, Valeria https://orcid.org/0000-0002-1163-7467
Gallego, John F. Jaramillo https://orcid.org/0000-0002-3464-9276
Varela, Carlos F. https://orcid.org/0000-0002-8745-3752
Greloni, Gustavo https://orcid.org/0000-0003-3930-467X
Rosa, Javier https://orcid.org/0000-0003-3331-0761
Soriano, Enrique R. https://orcid.org/0000-0003-3143-1084
- License Information
-
More Information
Article History
Received: 27 July 2022
Accepted: 4 January 2023
First Online: 13 January 2023
Declarations
:
: Gelsomina Alle declares that she has no conflict of interest. Marina Scolnik reports grants, personal fees and support for attending meetings from Janssen, grants and personal fees from GSK, personal fees and support for attending meetings from Roche, personal fees and support for attending meetings from Pfizer, and personal fees from Lilly, outside the submitted work. Valeria Scaglioni declares that she has no conflict of interest. John F. Jaramillo Gallego declares that he has no conflict of interest. Carlos F. Varela declares that he has no conflict of interest. Gustavo Greloni declares that he has no conflict of interest. Javier Rosa declares that he has no conflict of interest. Enrique R. Soriano reports grants and personal fees from Novartis, grants, personal fees and support for attending meetings from Pfizer, grants and personal fees from Amgen, personal fees and support for attending meetings from Abbvie, grants from Elea, personal fees and support for attending meetings from UCB, personal fees and support for attending meetings from Janssen, personal fees from BMS, personal fees from Eli Lilly, and personal fees from Sandoz, outside the submitted work. This study has been presented as a poster in the 2019 ACR/ARP Annual Meeting, abstract #2625: Alle G, Jaramillo Gallego J, Scolnik M, Scaglioni V, Brom M, Varela C, Greloni G, Soriano E. Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement [abstract]. <i>Arthritis Rheumatol.</i> 2019; 71 (suppl 10). .
